What is Character?
Character Biosciences, founded in 2020 and based in Jersey City, New Jersey, is a private precision medicine company dedicated to developing targeted therapies for progressive polygenic diseases. The company's initial focus areas include ophthalmology, specifically age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG). By leveraging a combination of genomics, extensive clinical data, and AI-driven modeling, Character Biosciences aims to enhance drug development success rates by pinpointing the genetic and molecular drivers of disease progression. This strategic approach positions the company at the forefront of personalized healthcare solutions.
How much funding has Character raised?
Character has raised a total of $136.9M across 3 funding rounds:
Other Financing Round
$18M
Private Equity
$8.9M
Series B
$110M
Other Financing Round (2022): $18M with participation from Innovation Endeavors and Section 32
Private Equity (2025): $8.9M, investors not publicly disclosed
Series B (2025): $110M supported by KdT Ventures, Luma Group, S32, Bausch & Lomb, Catalio Capital Management, aMoon, and Innovation Endeavors
Key Investors in Character
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials. They often provide the first institutional check into companies, leading or co-leading pre-seed and seed funding rounds.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. Founded by George Petrocheilos and Dr. Jacob Vogelstein, the firm focuses on breakthrough biomedical technology companies.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders, transformational technologies and emergent ecosystems. The firm's central investment thesis, the Super Evolution, combines data, leading-edge computation, and advanced engineering to transform industries.
What's next for Character?
The substantial enterprise-level funding and recent strategic investment indicate that Character Biosciences is poised for significant scaling and further research and development. This capital will likely fuel the advancement of their targeted therapies through clinical trials and expand their therapeutic pipeline. The company's focus on integrating advanced technologies like AI and genomics suggests a forward-thinking strategy aimed at addressing complex genetic diseases, positioning them for continued growth and potential market leadership in the precision medicine space.
See full Character company page
